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Abstract
Introduction: A wide variety of atypical antipsychotic drugs (risperidone, olanzapine, quetiapine, aripiprazole,
ziprasidone and clozapine) are widely used in the management of neuropsychiatric symptoms, which are
commonly seen in dementia, but results from randomised controlled trials (RCTs) on the efficacy and safety of
these agents are conflicting. We aimed to quantify the efficacy and safety of atypical antipsychotic drugs on
neuropsychiatric symptoms in dementia patients.
Methods: PubMed, EMBASE, the Cochrane Controlled Trials Register and the Cochrane Database of Systematic
Reviews for reports published before August 2014 were searched for eligible randomized controlled trials of atypical
antipsychotic drugs therapy in patients with psychotic symptoms of dementia. Two reviewers independently
assessed the quality of the trials and extracted information.
Results: Overall, 23 relevant RCTs with 5,819 participants were identified. This meta-analysis demonstrated a
significant efficacy of atypical antipsychotics on psychiatric symptoms and cognitive functions compared to
placebo. In the meta-analysis, the weighted mean differences (WMDs) in change scores for psychiatric symptoms
were in favor of aripiprazole (−4.4, 95% confidence interval (CI) – 7.04 to −1.77) and risperidone (−1.48, 95% CI −2.35
to −0.61) compared to placebo. In cognitive effects, WMDs in change scores for the Clinical Global Impression-Change
(CGI-C) were in favor of aripiprazole, risperidone, olanzapine and quetiapine which ranged from a −0.30 points mean
difference (95% CI:-0.59 to −0.01) in the aripiprazole trials to −0.43 (95% CI:-0.62 to −0.25) in the risperidone group.
Patients receiving atypical antipsychotics showed no difference in risk for injuries or falls (P > 0.05), significantly higher
risks (P < 0.05) for somnolence, urinary tract infection, edema and abnormal gait. However, there was no significant
evidence for death reported.
Conclusion: Aripiprazole and risperidone are able to improve psychiatric symptoms and slow decline in cognition
function at average 12 weeks in patients with neuropsychiatric symptoms of dementia. However, high adverse events
may offset the efficacy of atypical antipsychotics in dementia.
Introduction
The global prevalence of dementia is as high as 24 million
cases worldwide and has been predicted to quadruple by
the year 2050. Dementia causes unestimated healthcare
costs per year [1]. Neuropsychiatric symptoms rather than
cognitive dysfunction or functional impairment have been
suggested to impose the greatest burden on family care-
givers, and to predict caregivers’ decisions to institutio-
nalize patients with dementia. Interventions targeting
improving neuropsychiatric symptoms could therefore
have a tremendous impact on patients, caregivers and
society. There are multiple classes of pharmacological
agents in use for neuropsychiatric symptoms, especially
antipsychotics. The typical antipsychotic medications
(for example, haloperidol or thioridazine), with or without
psychosocial and environmental interventions, are fre-
quently used to treat symptoms that occur in a majority of
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older patients with dementia during their illness courses,
and have been the mainstay of psychopharmacologic
treatment during the last several decades [2]. Interestingly,
the atypical antipsychotics (that is, risperidone, olanza-
pine, quetiapine, aripiprazole, ziprasidone and clozapine)
generally have replaced conventional antipsychotics [3].
Atypical antipsychotics are approved for marketing and la-
beling by the US Food and Drug Administration for treat-
ing schizophrenia, bipolar disorder and depression under
drug-specific circumstances [4]. To date, the use of atyp-
ical antipsychotic medications is rapidly increasing in the
USA. They have been considered the preferred pharmaco-
logic treatment for behavioral disturbances associated with
dementia because evidence from clinical trials perceived
safety advantages compared with other medications and
expert clinical opinion [5].
The role of currently available atypical antipsychotics
for dementia has been controversial, however, with some
national formularies restricting their use and health eco-
nomists questioning whether the small clinical effects
are economically worthwhile. Moreover, the efficacy of
ziprasidone and clozapine in the treatment of dementia
has also been heavily debated. In addition, high dropout
rates and numerous adverse events have been observed
in randomized clinical trials of these agents. Besides,
safety concerns have been raised about the atypical anti-
psychotics. Some clinical trials and meta-analyses have
evaluated the efficacy and safety of these drugs on neu-
ropsychiatric symptoms, but have had conflicting find-
ings [6]. We thus performed a systematic review and
meta-analysis to clarify the efficacy and safety of these
atypical antipsychotics for neuropsychiatric symptoms in
dementia patients. We sought to elaborate on previous
reviews articles by including a broad spectrum of out-
come measures, and to determine whether these drugs
have different degrees of efficacy on psychiatric symp-
toms and cognitive functions of dementia. Previous sys-




The search strategy was described in detail. Briefly, we
systematically searched PubMed, EMBASE, the Cochrane
Controlled Trials Register and the Cochrane Database of
Systematic Reviews for reports published before August
2014. The search criteria combined three separate do-
mains: condition (dementia), intervention (risperidone,
olanzapine, quetiapine, aripiprazole, ziprasidone, cloza-
pine) and symptoms (behavioral and psychological symp-
toms of dementia, BPSD, neuropsychiatric symptoms,
behavior). We included studies reporting overall symp-
toms of agitation, psychosis or aggression. Terms were
searched in titles and abstracts. We retrieved English-
language articles for review, and also collected additional
references from bibliographies of reviews, original re-
search articles and other articles of interest. Pharmaceut-
ical manufacturers were queried and information was
requested as needed.
Two investigators independently reviewed all pertinent
articles using predetermined inclusion criteria. Trials
were selected for inclusion if they met all of the fol-
lowing criteria: parallel group, double-blind, placebo-
controlled, randomized controlled trials (RCTs); patients
had psychiatric symptoms with Alzheimer’s disease (AD),
vascular dementia, mixed dementia or a primary dementia
according to the Diagnostic and Statistical Manual of
Mental Disorders – Fourth Edition [7]; and the number of
patients randomized and at least one outcome measure or
adverse event were obtainable.
Trials selection
We selected double-blind, placebo-controlled RCTs
comparing atypical antipsychotics with placebo that used
the scales. Generally, trials of specific drugs used dif-
ferent outcomes from trials of other drugs. The Brief
Psychiatric Rating Scale (BPRS) [8] and the Neuro-
psychiatric Inventory (NPI) [9] are used mainly for ari-
piprazole trials, olanzapine trials, some quetiapine trials
and few risperidone trials. The Behavioral Pathology in
Alzheimer’s Disease Rating Scale (BEHAVE-AD) [10] and
the Cohen-Mansfield Agitation Inventory (CMAI) [11]
were generally used for risperidone trials. The Clinical
Global Impression – Change (CGI-C) and the Clinical
Global Impression – Severity (CGI-S) [12] were also used
as clinical outcomes in some trials. We used the NPI-total
score, BPRS-total score and BEHAVE-AD score as the
psychiatric symptoms, while the CGI-C and Minimum
Mental State Examination (MMSE) were used as the cog-
nitive functions. There is little clinical trial evidence for
the efficacy of ziprasidone and clozapine [6].
Data retrieval
Information extracted included design characteristics,
selection criteria (dementia diagnoses and presence of
psychosis of dementia), medication doses, trial durations
(6 to 26 weeks), age, race, gender, baseline cognitive
scores, baseline neuropsychiatric symptoms and num-
bers randomized. The minimum baseline score for the
NPI-total and the BPRS-total was 20 while that for the
BEHAVE-AD was 15. For each trial, two reviewers were
blinded to the authors and journal, and independently
abstracted data. The mean change of scale scores and
standard deviations for the mean change were extracted.
For standard deviations that were not reported directly,
we sought them from the authors or calculated them
from standard errors, confidence intervals (CIs) or P values
that relate to the difference between means in two groups










according to the Cochrane Handbook for Systematic Re-
views of Interventions [13]. Studies were excluded if the mean
change of scale total scores were not available. Moreover, if
there were duplicate publications from the same popula-
tion, only one of the trials that reported the mean change
of scale total score and standard deviation was included;
others were excluded. Outcomes and adverse events data
were from the intent-to-treat or last-observation-carried-
forward samples. Discrepancies in the collected data were
discussed, and if consensus was not reached a third re-
viewer was the final arbitrator.
Statistical analysis
Meta-analyses were performed using Review Manager
V.5.2 software (Review Manager, Version 5.2, Copenhagen:
The Nordic Cochrane Centre, The Cochrane Collabor-
ation, Denmark). Combining the scales in an overall sum-
mary estimate, we calculated weighted mean differences
(WMDs) and 95% CIs for changes from baseline for con-
tinuous data. For dichotomous dropouts and adverse
events, we conducted an analysis of the odds ratio (OR),
absolute risk differences with 95% CI and P values to as-
sess the safety of the study drug. A random-effects model
was applied to assess the effect sizes for each treatment–
placebo comparison in our study.
Because there were few dose-ranging trials and sparse
outcomes for adverse events, and to avoid multiple com-
parisons with the same placebo group, we combined
dosage groups within each trial to make one contrast
with placebo according to the Cochrane Handbook for
Systematic Reviews of Interventions. The degree of het-
erogeneity was assessed by visual inspection, and by a
chi-square test combined with the I2 method. The I2
statistic approximates the proportion of total variation
in the effect size estimates that is the result of hete-
rogeneity rather than sampling error. Values of α error
P <0.20 and I2 > 50% were regarded as indicators of hete-
rogeneity of outcomes.
Results
Characteristics of included trials
The results of the search process are depicted in the
flowchart (Figure 1). Of 886 articles identified, three aripi-
prazole articles [14-16], five olanzapine articles [17-21],
seven quetiapine articles [17,19,22-26] and eight risperi-
done articles [17,19,20,27-31] met all review criteria. All
studies were RCTs and were performed mainly in North
American and European countries. Baseline characteristics
were similar between intervention and placebo groups in
all of the trials. The included studies were all randomized
parallel trials for which the duration was 6 to 26 weeks. In
all, 13 trials compared one fixed dose of medicine and pla-
cebo, and five trials were dose ranging. Among these
dose-ranging studies, three used more than one dose
compared with a single placebo group. These trials in-
cluded 3,927 patients in the medicine treatment group
and 1,892 participants in the placebo treatment group.
The mean ages of patients in the medicine treatment
groups ranged from 77.3 to 84.2 years. The mean baseline
MMSE scores ranged from 4.8 to 15.7. Additional file 1
presents characteristics of these studies and populations
in more detail.
Bias risk assessment
Although all included trials were randomized, double
blinded and placebo controlled, specification of rando-
mization and allocation concealment methods were differ-
ent from each other. The randomization was conducted
according to a computerized randomization schedule
among nine trials, four reports specified the varied
methods of randomization and the other 14 reports did
not give detailed information although they involved
noted randomization. Besides, efficacy outcomes of all
trials were analyzed by intent-to-treat data with the
last-observation-carried-forward method for minimiz-
ing effects of attrition bias. A funnel plot did not show
evidence of selection bias with symmetry around the
mean overall effect.
Psychiatric symptoms
For psychiatric symptoms, 15 studies measured and re-
ported the mean change in NPI-total score from baseline
to end point for intervention compared with placebo:
three studies on aripiprazole [14-16], five studies on
olanzapine [17-21], two studies on quetiapine (50 mg)
[17,19], three studies on quetiapine (100 mg) [22,23,25]
and two studies on risperidone [17,19]. All of these studies
included participants with moderate to severe dementia.
NPI-total scores were only significant for aripiprazole by
meta-analysis in the available data (−4.4, 95% CI = −7.04
Figure 1 Flowchart of randomized controlled trials included
and excluded in the meta-analysis. RCT, randomized
controlled trial.










to −1.77). In the quetiapine trials, the differences by
meta-analysis were −4.3 (95% CI = −8.81 to 0.21) for the
50 mg daily group and −0.12 (95% CI = −1.74 to 1.50)
for the 100 mg daily group. In addition, the difference
between the olanzapine group and placebo was −2.61
(95% CI = −5.23 to −0.00) (Figure 2). The pooled study
NPI-total score was −1.68, which was of great signifi-
cance (P = 0.004). Fourteen trials used the BPRS-total
score: three studies on aripiprazole [14-16], five studies on
olanzapine [17-21], two studies on quetiapine (50 mg)
[17,19], two studies on quetiapine (100 mg) [23,25] and
two studies on risperidone [17,19]. The score was only
significant for aripiprazole by meta-analysis in the avail-
able data (95% CI = −3.44 to −0.62). In the quetiapine
trials, the differences by meta-analysis were −1.82 (95%
CI = −4.00 to 0.36) for the 50 mg daily group and −2.23
(95% CI = −4.83 to 0.38) for the 100 mg daily group. In
addition, the difference between the olanzapine group and
placebo was −0.60 (95% CI = −1.98 to 0.78) (Figure 3).
Only four risperidone trials reported changes in the
BEHAVE-AD score [27-30]. The BEHAVE-AD scores
were significant for risperidone by meta-analysis in the
available data. The WMDs by meta-analysis were −1.48
(95% CI = −2.35 to −0.61) (Figure 4). Furthermore, the
Figure 2 Forest plot for efficacy of the Neuropsychiatric Inventory-total score on dementia patients in subgroup analyses. Data type,
continuous; effect measure, weighted mean difference; analysis model, fixed effects; statistical method, inverse variance. CI, confidence interval;
SD, standard deviation.










Figure 3 Forest plot for efficacy of the Brief Psychiatric Rating Scale-total score on dementia patients in subgroup analyses. Data type,
continuous; effect measure, weighted mean difference; analysis model, fixed effects; statistical method, inverse variance. CI, confidence interval;
SD, standard deviation.
Figure 4 Forest plot for efficacy of the Behavioral Pathology in Alzheimer’s Disease Rating Scale score on dementia patients in
subgroup analyses. Data type, continuous; effect measure, weighted mean difference; analysis model, fixed effects; statistical method, inverse
variance. CI, confidence interval; SD, standard deviation.










effects with four drugs (risperidone, olanzapine, quetia-
pine, aripiprazole) on specific psychosis subscales of the
BPRS (see Additional file 2), NPI (see Additional file 3)
or BEHAVE-AD (see Additional file 4) were analyzed.
There were no significant effects by meta-analysis for
three aripiprazole trials, three olanzapine trials, one ris-
peridone trial and one quetiapine trial on the NPI psy-
chosis subscales (WMD= −0.42, 95% CI = −0.91 to 0.08,
P = 0.29). However, aripiprazole trials alone showed a sig-
nificant effect on NPI psychosis subscales (WMD= −0.88,
95% CI = −1.61 to −0.16, P = 0.02). For aripiprazole, the
BPRS psychosis subscale scores by meta-analysis were
not significant (WMD = −0.23, 95% CI = −0.60 to 0.08,
P = 0.23). There was a significant effect by meta-analysis
with risperidone on the BEHAVE-AD psychosis subscale
from four trials (WMD= −0.84, 95% CI = −1.24 to −0.44,
P <0.0001). The quality of reports for all included studies
was appraised with GRADE software (Grading of Recom-
mendations Assessment, Development and Evaluation,
Version 3.6, Hamilton, Canada), and the outcome is
presented in Additional files 5, 6 and 7.
Cognitive functions
Thirteen studies measured and reported the mean change
in CGI-C from baseline to end point for intervention
compared with placebo: one study on aripiprazole [15],
three studies on olanzapine [17,19,21], five studies on
quetiapine [19,22-25] and four studies on risperidone
[17,19,27-30]. CGI-C scores were all significant for these
trials by meta-analysis in the available data. The difference
between the pooled group and placebo was −0.36 (95%
CI = −0.47 to −0.25) (Figure 5). Furthermore, 13 trials
Figure 5 Forest plot for Clinical Global Impression – Change subscale scores on dementia patients in subgroup analyses. Data type,
continuous; effect measure, weighted mean difference; analysis model, fixed effects; statistical method, inverse variance. CI, confidence interval;
SD, standard deviation.










reported MMSE change scores: three aripiprazole con-
trasts [14-16], three olanzapine contrasts [17,18,20], two
risperidone contrasts [17,20] and five quetiapine contrasts
[19,22-25]. The overall effect of drugs compared with
placebo was a WMD of −0.34 (95% CI = −0.65 to −0.03,
P = 0.03) in favor of placebo. The three aripiprazole trials
showed statistical significance of MMSE in favor of pla-
cebo (WMD= −0.99, 95% CI = −1.65 to −0.33, P = 0.003)
(Figure 6). The quality of reports for all included studies
was appraised with GRADE software. The outcome is
presented in Additional files 8 and 9.
General assessment of atypical antipsychotic drugs
Aripiprazole
The three aripiprazole trials retrieved were designed simi-
larly, with similar selection criteria – AD with psychosis
and 10-week treatment durations – and the same primary
and secondary outcomes – that is, BPRS, NPI, CGI-S and
CMAI. Two were nursing home trials and one was an
outpatient trial. One trial was a dose-ranging trial in-
cluding 2, 5 and 10 mg/day [15]. Significant effects by
meta-analysis were observed on the BPRS-total and
NPI-total change scores (WMD = −4.4, 95% CI = −7.04
to −1.77, P= 0.001; WMD= −2.03, 95% CI = −3.44 to −0.62,
P = 0.005). A significant effect by meta-analysis on the
CMAI was observed but was based on only the two nurs-
ing home trials (WMD= −4.73, 95% CI = −7.43 to −2.03,
P = 0.0006). Global clinical ratings were reported only as
continuous outcomes with a one-point to seven-point
range and not as categorical or individual response-based
outcomes. The CGI-S was significant in favor of aripi-
prazole by meta-analysis (WMD = −0.16, 95% CI = −3.0
to −0.03, P = 0.02). The heterogeneity among the study
was mild (I2 = 0%).
Figure 6 Forest plot for Minimum Mental State Examination in dementia patients. Data type, continuous; effect measure, weighted mean
difference; analysis model, fixed effects; statistical method, inverse variance. CI, confidence interval; SD, standard deviation.











Among the five olanzapine trials, four trials retrieved
were designed with similar selection criteria – AD with
psychosis, 6-week to 12-week treatment durations – and
the same primary outcomes – that is, BPRS and NPI.
Two were nursing home trials and three were out-
patient trials. Three trials chose patients with psychotic
and behavioral symptoms. Other two trials focused on pa-
tients with psychosis, aggression or agitation. Two trials
were dose-ranging trials including 5, 10 and 15 mg/day
and 5 and 7.5 mg/day respectively. We only chose the
average 5 mg/day group for meta-analysis.
Among these five trials, there were nonsignificant effects
by meta-analysis on the BPRS and NPI (WMD= −0.6,
95% CI = −1.98 to 0.78, P = 0.40; WMD = −2.61, 95%
CI = −5.23 to 0.00, P = 0.05;respectively).
Quetiapine
The designs, selection criteria and outcomes scales dif-
fered substantially among the seven quetiapine trials and
we combined the same dose group for efficacy out-
comes. One study enrolled primarily nursing home pa-
tients with psychosis in patients with probable/possible
AD and assessed other psychopathology and social and
daily functioning [23]. Four trials chose patients with a
primary dementia, AD, vascular dementia or mixed de-
mentia, mainly manifesting agitation severe enough to re-
quire an antipsychotic. Among the four trials, a smaller
trial chose nursing home patients with AD and agitation
and compared quetiapine treatment with rivastigmine
and placebo [26]. The other two trials focused on the
behavioral and psychological symptoms of dementia
patients [17,24].
Two trials showed no significant effect for the 50 mg/
day quetiapine treatment groups on the BPRS and NPI
(WMD = −1.82, 95% CI = −4.00 to 0.36, P = 0.10;
WMD = −4.3, 95% CI = −8.81 to 0.21, P = 0.06; respect-
ively). Three trials showed no statistically significant
effect for the 100 mg/day quetiapine treatment groups
on the BPRS and NPI (WMD = −0.12, 95% CI = −1.74
to 1.50, P = 0.89; WMD = −2.23, 95% CI = −4.83 to
0.38, P = 0.09; respectively).
Risperidone
Among the eight risperidone trials, four were similarly
designed in that they selected nursing home patients
with dementia and aggression, had a minimum score on
the BEHAVE-AD of ≥8 and were treated for an average
12 weeks. Three trials enrolled AD patients with psy-
chotic and behavioral symptoms. Schneider and col-
leagues’ trial selected patients with psychosis. These
eight trials used similar primary efficacy outcomes; that
is, the BEHAVE-AD and CMAI. The CGI-C, CGI-S,
NPI and BPRS were also used as secondary outcomes
in some trials.
Among the four trials using the BEHAVE-AD, there
was overall significant improvement with risperidone
(WMD = −1.48, 95% CI = −2.35 to −0.61, P = 0.0008) and
on the CMAI used in three trials (WMD = −3.00, 95%
CI = −4.22 to −1.78, P <0.00001). There was a statistically
significant effect overall by meta-analysis on the CGI-S in
two trials as a continuous variable (WMD= −0.39, 95%
CI = −0.58 to −0.20, P <0.0001). However, no significant
difference was observed for the NPI or BPRS score.
Safety
Adverse events
Adverse events were inconsistently reported among the
trials; most did not report adverse events occurring less
than 20% of the time, and potentially significant adverse
events could not be counted from all trials. Somnolence,
falls, injury, edema and urinary tract infections were
mostly reported from the trials. Adverse events are sum-
marized by the numbers of trials for which the event
was reported and the odds ratio for the event (Table 1).
The quality of reports of all included studies was ap-
praised with GRADE software, and the outcome is pre-
sented in Additional file 10.
Table 1 Odds ratios by meta-analysis of adverse effects in atypical antipsychotics compared with placebo
Somnolence Injuries or falls Abnormal gait Edema Urinary infection Stroke
Aripiprazole OR 3.51 0.86 5.04 0.93 1.20 1.58
(95% CI) (1.64, 7.5) (0.58, 1.28) (0.58, 43.81) (0.38, 2.27) (0.78, 1.87) (0.38, 6.55)
Olanzapine OR 3.61 1.13 3.84 0.52 6.93 3.93
(95% CI) (1.83, 7.13) (0.72, 1.76) (1.64, 8.95) (0.16, 1.69) (1.33, 35.96) (0.62, 25.10)
Risperidone OR 3.57 0.85 1.21 0.49 2.28 4.53
(95% CI) (2.72, 4.67) (0.68, 1.08) (0.73, 1.99) (0.30, 0.78) (1.58,3.30) (1.75, 11.72)
Quetiapine OR 5.88 0.86 1.98 1.51 1.90 1.13
(95% CI) (2.39, 14.47) (0.57, 1.29) (0.73, 5.39) (0.55, 4.19) (0.95, 3.8) (0.36, 3.56)
CI, confidence interval; OR, odds ratio.











The 13 available comparisons all showed increased risk
for somnolence, and all of them were statistically sig-
nificant. The odds ratio by meta-analysis was 3.7 (95%
CI = 2.94 to 4.66, P <0.00001) with significant hetero-
geneity. Significant risk differences were found among
aripiprazole (OR = 3.51, 95% CI = 1.64 to 7.50), olanza-
pine (OR = 3.61, 95% CI = 1.83 to 7.13) and quetiapine
(OR = 5.88, 95% CI = 2.39 to 14.47) with small hetero-
geneity (I2 = 0%).
Injury or falls
Outcomes are consistent in the 15 contrasts that pro-
vided data for injury/accidental injury and falls. They did
not show an increase or decrease in risk overall or in the
result of a particular drug or trial (OR = 0.89, 95% CI =
0.75 to 1.05, P = 0.17).
Abnormal gait
There was an overall increased risk for abnormal gait in
the pooled analysis (OR = 1.84, 95% CI = 1.26 to 2.68,
P = 0.002) from 10 trials. There was increased risk in
three olanzapine trials, and no increased risk in one ari-
piprazole trial, three risperidone trials and three quetia-
pine trials.
Edema
Nine trials reported edema. Increased risks was observed
by meta-analysis for edema (OR = 0.63, 95% CI = 0.44 to
0.91, P = 0.01). The increased risk was associated with
risperidone. Two of three aripiprazole trials, three of five
olanzapine trials, four of eight risperidone trials and five
of seven quetiapine trials did not report edema.
Urinary tract infections
Urinary tract infections were reported in 11 contrasts,
including three aripiprazole trials, two olanzapine trials,
four risperidone trials and two quetiapine trials. There
was overall increased risk for urinary tract infections in
the antipsychotic-treated patients (OR = 1.91, 95% CI =
1.48 to 2.46, P <0.00001). The effect was not significant
with aripiprazole and quetiapine, but was significant
when the events were combined. Urinary tract infections
were not reported in one olanzapine trial (one trial in-
cluded risperidone), but urinary incontinence both was
and was not reported in the trials of the other drugs.
Stroke
Stroke was reported in 13 contrasts including three
aripiprazole trials, two olanzapine trials, four risperidone
trials and four quetiapine trials. There was overall
increased risk for stroke in the antipsychotic-treated
patients. Meta-analysis demonstrated a significantly
higher risk of stroke in the pooled antipsychotic group
(OR = 2.62, 95% CI = 1.45 to 4.75, P = 0.001) and in the
risperidone subgroup (P = 0.002). However, the effect
was not significant with aripiprazole, olanzapine and
quetiapine (see Additional file 11).
Deaths
The overall OR by meta-analysis for death in patients
treated with antipsychotics compared with placebo was
1.06 (95% CI = 0.65 to 1.73; Z = 0.24, P = 0.81). There
was no increased risk of death with any individual drug.
Besides, in most studies, adverse reactions occurring in
less than 20% of patients were not taken into account
when not finding a significantly higher prevalence of
mortality.
All-cause dropouts
In overall meta-analyses on safety, there were no signifi-
cant differences in the number of dropouts caused by
any reason between any medicine treatment group and
placebo treatment group (OR = 0.95, 95% CI = 0.82 to
1.09; Z = 0.75, P = 0.45). In subgroups, we observed simi-
lar results (aripiprazole, 95% CI = 0.63 to 1.39; olanza-
pine, 95% CI = 0.57 to 1.13; risperidone, 95% CI = 0.79 to
1.22; quetiapine, 95% CI = 0.74 to 1.36) (see Additional
file 12).
Discussion
Psychiatric symptoms occur on average in 70% of demen-
tia patients during the primary illness [6]. The use of
atypical antipsychotic medications is therefore increas-
ing rapidly. Atypical antipsychotics have been consid-
ered preferred pharmacologic treatments for behavioral
disturbances associated with dementia because of clinical
trial evidence for perceived safety advantages compared
with other medications and expert clinical opinion. How-
ever, the role of currently available atypical antipsychotics
for dementia has been controversial and health econo-
mists always question whether the small clinical effects
are economically worthwhile. In our present study, we
have obtained the treatment effects of 23 trials including
5,819 patients with dementia. Our results show obvious
benefits for symptomatic efficacy on psychiatric symptoms
and cognitive functions of aripiprazole and risperidone
after statistically combining the trials. The safety of atyp-
ical antipsychotics may offset the usage of drugs.
A previous study by Schneider and colleagues analyzed
15 RCTs (from published articles or presentations at
medical meetings) of three aripiprazole trials, five olan-
zapine trials, three quetiapine trials and four risperidone
and found modest benefits for aripiprazole and risperi-
done, but also that adverse events and dropouts blocked
their efficacy [32]. Furthermore, Maher and colleagues
conducted a meta-analysis on efficacy and comparative
effectiveness of atypical antipsychotics for off-label uses









in psychosis, agitation and global behavioral symptoms
in dementia. They found small but statistically signifi-
cant pooled effect size for aripiprazole, olanzapine and
risperidone [33]. A previous paper indicated that aripi-
prazole shows modest efficacy in the treatment of AD-
related psychosis [34]. The benefit of aripiprazole in
dementia was consistent in the previous study and our
meta-analysis. However, olanzapine was not associated
with efficacy overall in our study. Besides, there was a
lack of evidence for or against quetiapine because five
among the seven trials were dose-ranging and used dif-
ferent selection criteria. The outcomes could not be
statistically combined using a common rating scale.
Furthermore, Katz and colleagues found that risperi-
done showed improvement in psychotic symptoms and
general clinical improvement in patients with psychosis
of AD [28]. However, in our study, risperidone showed
improvement in behavior symptoms on dementia. In
addition, aripiprazole, olanzapine and quetiapine were
more effective for particular symptoms, such as anger
and aggression. They all proved to have significant ef-
fect on neuropsychiatric symptoms in early studies. As
a result, our study is in line with findings from a former
review [32] and long-standing clinical experience.
The duration of RCTs of atypical antipsychotics varies
from 6 to 26 weeks. Because the length of treatment as
well as methodological factors may be stronger outcome
modifiers, a considerable number of placebo-controlled
RCTs of atypical antipsychotics for stabilizing or slowing
decline in psychiatric symptoms and cognitive functions
of patients with dementia have been undertaken for gen-
erally 6 to 12 weeks in this study. The possible methodo-
logical factors that may be relevant as strong outcome
modifiers are publication bias or different randomization
methods. We only focused on published English-language
studies and there are additional unpublished studies that
have been identified, which may have introduced a pub-
lication bias in favor of studies showing benefits with
medications [32]. In addition, although the studies in-
cluded were randomized, they may not apply the same
randomization method.
Safety is as important as the efficacy of the interven-
tions in clinical studies. The five main adverse events
were analyzed here and the pooled study showed evidence
in increasing somnolence, edema, urinary infection and
abnormal gait. Patients receiving atypical antipsychotics
showed no difference in risk for injuries or falls (P >0.05),
and significantly higher risks (P <0.05) for somnolence,
urinary tract infection or urinary incontinence, edema and
abnormal gait. Notably, risperidone had a higher risk on
adverse events. However, no drugs improved or aggra-
vated injuries or falls compared with placebos. These
events were usually of mild or moderate severity, and the
risk disappeared on serious adverse events. Finally, none
of these drugs seemed to increase the risk of death in this
study, yet the difference did not achieve statistically sig-
nificant levels. Similarly, Schneider and colleagues found a
significant risk for somnolence, abnormal gait, edema,
urinary tract infection or urinary incontinence on atypical
antipsychotics versus placebo [32]. In general, the results
of our meta-analysis demonstrated statistical increased
risks of 1.1-fold to 1.5-fold for these adverse events. Thus,
an increased risk of AEs in atypical antipsychotics is ob-
served during these years. Importantly, a follow-up study
indicated that there was an increased long-term risk of
mortality in patients with AD who are prescribed anti-
psychotic medication [35]. These results further supported
the need to seek less harmful alternatives for the long-
term treatment of neuropsychiatric symptoms in dementia
patients.
Although previous systematic reviews or meta-analysis
have been reported, atypical antipsychotics produced
modest benefits on neuropsychiatric outcomes. To date,
we perform a more comprehensive analysis covering a
variety of outcome domains that included many previous
studies without a higher risk of bias. Besides, we identi-
fied and included five recent studies to conduct an up-
dated meta-analysis, and our results further supported
this. There was some evidence to support the efficacy of
the atypical antipsychotics when compared with placebo
on change in neuropsychiatric symptom scores in the
previous reviews [36,37]. These trials offered updated
information of atypical antipsychotics in psychiatric
symptoms and cognitive functions, which may have
contributed to the differences between our review and
previous reviews. More importantly, compared with the
previous reviews, our study added quality assessment
analysis. Quality assessment by GRADE software was
used to establish the robustness of the primary out-
come, and higher robustness means study drugs have
more definite effects on the diseases. Because the mag-
nitude of statistical effect does not always imply a similar
magnitude clinical effect, we also reviewed and analyzed
each drug separately and by specific outcomes to better
address the psychiatric symptoms (see Additional files 13,
14, 15 and 16).
Several limitations to our meta-analysis restrict the in-
terpretation of our results. First, some of our included
trials excluded participants receiving psychotropic medi-
cines, while some trials allowed, and even demanded,
the use of medicines such as cholinesterase inhibitors
and other drugs in their study. The use of such medicines
may have an impact on our results. In addition, dementia
is progressive and patients declined at progressive differ-
ent stages of severity, which may also influence our results
when pooling data. Finally, there still were very limited
trials per each study drug and dose in this present study;
unfortunately, some items tested in the trials were not










available in the results, and despite numerous attempts to
contact the authors, further details were still absent. In
addition, we must note that despite differences in out-
come measures such as the NPI and so forth, the outcome
symptoms may also differ among studies (such as agita-
tion and/of psychosis). Therefore, no convincing conclu-
sions can be drawn regarding the efficacy of these drugs
for neuropsychiatric symptoms. Furthermore, some trials
found no significant differences in outcomes between
the withdrawal of the drugs and continuation groups.
Decision-making related to antipsychotic drug treatment
in dementia remains challenging and requires a thoughtful
approach [38]. What is worth noting is that the heterogen-
eity was substantial for the outcomes. We detected a sub-
stantial heterogeneity in meta-analyses in NPI psychosis
or BPRS psychosis. There are several interpretations for
the heterogeneity. First, it may indicate that many dif-
ferences still exist between different kinds of dementia,
although they are highly identical in clinical and neuro-
pathological symptoms. The second sources of hetero-
geneity may be the discrepancy in treatment duration
and bias risk, and the diversity in concomitant patho-
logic condition and drug therapy.
Despite some limitations, we believe that our results
are the newest and most comprehensive attempt to quan-
titatively synthesize the efficacy and safety of atypical
antipsychotics for neuropsychiatric symptoms of dementia
patients, suggesting a moderate benefit in neuropsychiatric
outcomes from antipsychotics. Our meta-analysis results
indicate that for dementia patients who have neuropsychiatric
disturbances, atypical antipsychotics may be considered as a
therapeutic option. However, it is notable that the decision to
use these medicines needs to be considered in light of the
adverse effects, cost and feasibility. As recommended, for
dementia patients with neuropsychiatric symptoms, excluding
medical and environmental factors, drug therapy should be
used to manage neuropsychiatric symptoms. Overall, our
meta-analysis results indicate a benefit in neuropsychiatric
symptoms for dementia patients from atypical antipsychotics.
Conclusion
Obvious benefits were observed for symptomatic efficacy
on psychiatric symptoms and cognitive functions of ari-
piprazole and risperidone after statistically combining
the trials. The higher risks for adverse events may offset
the efficacy of atypical antipsychotics for treatment of
dementia. Hopefully, the design of a multicenter study
could use currently available levels of treatment and
care, in order to provide a broader generalizability of the
results in the future. Future research should focus more
on neuropsychiatric outcomes. It is important to continue
efforts to perform high-quality trials of drug therapy, and
the safety evaluation of the drugs cannot be ignored.
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